Pack size: Box of 10 Tablets  |  Price is for the whole Box

⚠ Prescription required. This medicine may only be dispensed against a valid prescription.

Generic: Avatrombopag

Form: Tablet 20mg

Indication

Thrombocytopenia

Administration

Take with food

Adult Dose

$4b

Renal Dose

Renal impairment Mild-to-moderate (CrCl ?30 mL/min): No dose adjustment required; minimally excreted by the kidneys Severe (CrCl <30 mL/min) or hemodialysis: Unknown

Mode of Action

Second-generation orally administered thrombopoietin receptor agonist (TPO-RA) Stimulates proliferation and differentiation of megakaryocytes from bone marrow progenitor cells, resulting in an increased production of platelets Does not compete with TPO for binding to the TPO receptor and has an additive effect with TPO on platelet production

Precaution

Thrombotic/thromboembolic complications Thrombopoietin (TPO) receptor agonists associated with thrombotic and thromboembolic complications in patients with chronic liver disease or chronic ITP Portal vein thrombosis reported with chronic liver disease in patients treated with thrombopoietin (TPO) receptor agonists (ADAPT-1 and ADAPT-2 clinical trials) Consider the potential increased thrombotic risk when administering to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (eg, factor V Leiden, prothrombin 20210A, antithrombin deficiency, or protein C or S deficiency) Not to be administered to patients with chronic liver disease or chronic immune thrombocytopenia in an attempt to normalize platelet counts; thromboembolic events (arterial or venous) reported Follow dosing guidelines to achieve target platelet counts; monitor patients receiving therapy for signs and symptoms of thromboembolic events and institute treatment promptly